Anebulo Pharmaceuticals
ANEB
ANEB was delisted on the 27th of February, 2026.
12 hedge funds and large institutions have $17.1M invested in Anebulo Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
9% more funds holding
Funds holding: 11 → 12 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1.79% less ownership
Funds ownership: 29.28% → 27.49% (-1.8%)
11% less capital invested
Capital invested by funds: $19.2M → $17.1M (-$2.09M)
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$421 |
| 2 |
Wells Fargo
San Francisco,
California
|
+$45 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
-$9.83K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$2.86K |
| 3 |
LA
LVW Advisors
Pittsford,
New York
|
-$2.77K |
| 4 |
Morgan Stanley
New York
|
-$2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
2L
1
22NW LP
Seattle,
Washington
| $12.3M | – | – | – |
|
|
LA
2
LVW Advisors
Pittsford,
New York
| $1.63M | -$2.77K | -1,050 | -0.2% |
|
|
NCM
3
Nantahala Capital Management
New Canaan,
Connecticut
| $1.24M | – | – | – |
|
|
MP
4
Mangrove Partners
Greenwich,
Connecticut
| $968K | – | – | – |
|
|
PCM
5
Praetorian Capital Management
Coral Gables,
Florida
| $436K | +$474K | +180,005 | New |
|
|
IC
6
Ikarian Capital
Dallas,
Texas
| $375K | – | – | – |
|
|
HIG
7
Herr Investment Group
Austin,
Texas
| $71.8K | +$78.1K | +29,644 | New |
|
|
BFM
8
Boothbay Fund Management
New York
| $42K | – | – | – |
|
|
9
BlackRock
New York
| $17.7K | +$421 | +160 | +2% |
|
|
TRCT
10
Tower Research Capital (TRC)
New York
| $9K | -$9.83K | -3,733 | -51% |
|
|
11
UBS Group
Zurich,
Switzerland
| $4.1K | -$2.86K | -1,085 | -39% |
|
|
12
Wells Fargo
San Francisco,
California
| $131 | +$45 | +17 | +46% |
|
|
13
Morgan Stanley
New York
| – | -$2K | -600 | Closed |
|
ANEB Hedge Fund Activity: Q4 2022 in Review
12 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Anebulo Pharmaceuticals (ANEB) for Q4 2022, worth a combined $17.1M — down 11% from $19.2M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new ANEB positions and 1 closed out — a net gain of 1 holder — while 2 added to existing stakes and 3 trimmed.
The largest buyer was BlackRock, adding an estimated $421. The largest seller was Tower Research Capital (TRC), cutting an estimated $9.83K.
- 12 institutional investors held Anebulo Pharmaceuticals (ANEB) as of Q4 2022, up from 11 in Q3 2022.
- Funds reported $17.1M of Anebulo Pharmaceuticals stock for Q4 2022, down 11% quarter-over-quarter.
- 2 funds opened new Anebulo Pharmaceuticals positions in Q4 2022 and 1 closed out, a net change of +1 holder.
- The largest Anebulo Pharmaceuticals buyer in Q4 2022 was BlackRock, an estimated $421 added.
- The largest Anebulo Pharmaceuticals seller in Q4 2022 was Tower Research Capital (TRC), an estimated $9.83K sold.
Based on aggregated 13F filings for Q4 2022.